Table S1. The baseline characteristics of patients included in the analysis with the subgroups of patients, who maintained 18 month remission or relapsed.

Parameters	All	Remission	Relapse	p	OR (95% CI)
N (%)	47	23 (48.9)	24 (51.1)	NA	NA
Women (%)	18 (38.3)	10 (43.5)	8 (33.3)	0.48	0.7 (0.2-2.1)
Age	32.5 (25.5-45.5)	28.0 (23.0-29.0)	35.5 (29.5-49.5)	0.11	1.0 (0.97-1.1)
Presence of fistulas (%) (after induction therapy)	14 (29.8)	2 (8.7)	12 (50.0)	0.003	10.5 (2.0-55.0)
Previous abdominal operations (%)	17 (36.2)	4 (17.4)	13 (54.2)	0.02	5.6 (1.5-21.5)
History of CD complications* (%)	25 (53.2)	6 (26.1)	19 (79.2)	<0.001	10.8 (2.8-41.8)
Smoking (%)	7 (14.9)	4 (17.4)	3 (12.5)	0.70	0.7

					(0.1-3.4)
Other chronic diseases (%)	18 (38.3)	6 (26.1)	12 (50.0)	0.09	2.8 (0.8-9.7)
PLT, G/L (before therapy)	344.0 (260.0-434.0)	320.0 (260.0-385.0)	347.0 (258.5-446.0)	0.57	1.0 (0.997-1.0)
PLT, G/L (after induction therapy)	281.0 (225.0-336.0)	277.0 (223.0-318.0)	295.5 (253.0-359.5)	0.18	1.0 (0.998-1.0)
MPV, fl (before therapy)	9.5 (8.9-10.1)	9.7 (9.4-10.5)	9.1 (8.9-9.9)	0.13	0.5 (0.2-1.2)
MPV, fl (after induction therapy)	9.8 (9.1-10.6)	10.4 (9.4-11.1)	9.5 (9.0-10.1)	0.01	0.4 (0.2-0.9)
MPV <10.4fl (%) (after induction therapy)	32 (68.1)	11 (47.8)	21 (87.5)	0.005	7.6 (1.8-32.9)
WBC, G/L (before therapy)	8.1 (6.3-10.6)	7.9 (5.7-10.4)	9.9 (7.4-10.8)	0.18	1.2 (0.9-1.4)
WBC, G/L (after induction therapy)	7.3 (5.4-9.0)	5.6 (5.1-7.8)	8.6 (5.8-10.3)	0.008	1.4 (1.1-1.9)
WBC >7.9G/L (%) (after induction therapy)	20 (42.6)	5 (21.7)	15 (62.5)	0.008	6.0 (1.7-21.8)

Data are presented as median (IQR) unless otherwise indicated.

* i.e. fistulas, abscesses, fissures, intestinal stenosis and obstruction

CD: Crohn's disease, CI: confidence interval, MPV: mean platelet volume, N: number of participants, NA: not applicable, OR: odd ratio, PLT: platelets, WBC: white blood cells. P relates to the difference between remission and relapse groups.